Overview
Sleuth Insights builds an AI-powered biopharma intelligence platform for strategic decision-making in pharmaceutical research and development. It combines a proprietary knowledge graph with over 100 million pre-linked data points from public and proprietary sources, covering drugs, clinical trials, deals, targets, indications, regulatory filings, transcripts, reports, news, and patents. Users can access done-for-you intelligence from Sleuth’s analysts or query the knowledge graph in natural language to export findings and build dashboards, with real-time hypothesis testing to identify related trials. The platform differentiates itself through its extensive, continuously validated data graph and the integration of AI querying with analyst-driven analysis, aiming to speed up data gathering and interpretation for commercial diligence and investment strategies under an annual retainer pricing model.
Work here?Claim your company
Simplify's Take
What believers are saying
- April 21, 2026 seed funding from Bison Ventures financed engineering and data expansion.
- October 2026 reports on protein degraders and in-vivo cell therapy show active product velocity.
- Updated on October 3, 2026, Sleuth sells directly to banks, consultants, and biotech teams.
What critics are saying
- The November 1, 2025 Form D signals continuous fundraising dependence before durable revenue.
- Consulting-style delivery caps margins and ties growth to analyst hiring through 2026.
- AlphaSense, Citeline, and PitchBook can bundle adjacent workflows, compressing Sleuth's pricing power.
What makes Sleuth Insights unique
- Sleuth launched from stealth on April 21, 2026 with proprietary biopharma knowledge graph.
- Sleuth combines analysts and software, delivering executive-ready diligence faster than consulting firms.
- Its natural-language interface turns drugs, trials, deals, and patents into searchable strategy views.
Help us improve and share your feedback! Did you find this helpful?